Estimate material coherent scatter form factors for voxels within a scan object by exposing a series of slices of the scan object to an X-ray fan beam within a coherent scatter scanner. Capturing coherent scatter data at a least two X-ray detector modules that are limited to a small-angle field of view by at least one detector-side angle limiting element to provide for capture of small-angle scatter over a wide field of view. Combining the coherent scatter data from the at least two X-ray detector modules to generate an aggregated collection of estimated material coherent scatter form factors for at least some voxels. Combining the aggregated collection of estimated material coherent scatter form factors with a model of aggregate items that clusters voxels in the scan object into model items. Using the aggregated collection of estimated material coherent scatter form factors to estimate a material type for individual model items.
G01N 23/201 - Measuring small-angle scattering, e.g. small angle X-ray scattering [SAXS]
G01N 23/046 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by transmitting the radiation through the material and forming images of the material using tomography, e.g. computed tomography [CT]
An excretion collection and evaluation system including at least one waste receptacle including a waste collection area. and a sensor configured to be coupled to a toilet, selectively coupled to the at least one waste receptable, and configured to generate a signal indicative of a quantity of waste deposited in the waste collection area.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G01F 23/20 - Indicating or measuring liquid level or level of fluent solid material, e.g. indicating in terms of volume or indicating by means of an alarm by measurement of weight, e.g. to determine the level of stored liquefied gas
Disclosed herein are compounds that have improved cellular specificity. The compounds have linkers and other moieties that can both aid in cellular specificity and that can attach functional groups to a target cell. The compounds can be used, e.g., in methods of modulating, detecting, and labeling of proteins and cells. An example method includes the compound forming a covalent bond with a dehalogenase variant.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
Disclosed herein are novel promoters that drive expression of a gene product preferentially in the heart and in skeletal muscle. Disclosed herein are vectors comprising these novel promoters and vectors comprising these novel promoters. Disclosed herein are methods of gene editing and gene therapy that employ these novel promoters and novel vectors.
Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07C 217/78 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
C07C 217/84 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
6.
ALLERGY VACCINE PLATFORM BASED ON SUPRAMOLECULAR MATERIALS
Embodiments are directed to a conjugate peptide including a self-assembling peptide and at least one allergen epitope. Allergen epitopes may include peanut allergens. The conjugate peptide may self-assemble into a nanofiber or fibril. Compositions including the conjugate peptide may be used to treat allergies.
A novel localized, mechanical HIFU (LM-HIFU) transcatheter device that can ablate cancer cells and disrupt the stromal barrier in tumors, enhancing the efficacy of therapeutics and increasing immune cell infiltration. A miniaturized dual-lumen catheter device is configured to deliver M-HIFU to a tumor that does not have the anatomic limitations of conventional HIFU, and enables access to a primary or metastatic tumor regardless of the location.
Disclosed herein are AAV chimeric capsid proteins that confer an ability to evade neutralizing antibodies in humans. Disclosed herein are compositions comprising AAV chimeric capsid proteins and methods of making and using the AAV chimeric capsid proteins
Disclosed herein are compositions and methods for modulating T cells. For example, the compositions and methods may be used to increase memory T cells. The compositions and method may be used in combination with Adoptive T Cell Therapy (ACT) to enhance the ACT.
The present disclosure describes, in part, an enzyme-mediated radical initiating system and methods of using the system to produce polymers, including polymeric hydrogels, at ambient conditions.
Disclosed herein are compositions comprising an interfering molecule and/or an anti-PD1 molecule and using those compositions in methods of preventing or inhibiting metastasis of cancer cells and methods of reducing the risk of developing metastases.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to coronavirus spike protein. Herein, monoclonal antibodies were recombinantly derived from isolated B cell from coronavirus infected individuals. Such antibodies bind various epitopes on the coronavirus spike protein and are neutralizing. The invention provides methods for using the inventive antibodies in prophylactic and/or therapeutic methods to prevent or treat coronavirus infection.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
This disclosure provides compositions and methods for detecting, methods for predicting a risk of developing, and methods for treating systemic and brain parenchymal metastases including leptomeningeal disease (LMD). In particular, provided herein are methods for detecting and/or predicting a risk of developing systemic and brain parenchymal metastases including LMD in a subject (e.g., a human subject) through identifying the presence or absence of integrin a6 and/or breast cancer cells (BCCs) expressing integrin a6 in a sample obtained from the subject. In addition, provided herein are methods for treating, ameliorating, or preventing systemic and brain parenchymal metastases including LMD in a subject through inhibiting expression and/or activity of one or more of integrin a6, BCCs expressing integrin a6, neuroprotective factor glial cell line-derived neurotrophic factor (GDNF), and neural cell adhesion molecule (NCAM).
Methods and compositions for promoting donor-specific tolerance and immunocompetence to a recipient of a solid organ transplant, by implanting an allogeneic solid organ in a recipient in need of a solid organ transplant and further comprising surgical implantation of a tissue-engineered allogeneic cultured postnatal thymus tissue product in the recipient of a solid organ from a donor. Methods of producing an allogeneic cultured postnatal thymus tissue-derived product suitable for implantation into a human; methods of culturing allogeneic cultured postnatal thymus tissue-derived product suitable for implantation into a human and methods of using allogeneic cultured postnatal thymus tissue-derived product by implantation in a human subject.
Disclosed herein are compositions for and gene therapy methods of treating and/or preventing glycogen storage disease progression including the progression of GSD IV and/or APBD. Also disclosed herein are compositions for and gene therapy methods of preventing glycogen accumulation and/or degrading accumulated glycogen.
Disclosed herein are mechanoenhancers and compositions and methods for modulating expression of a mechanoenhancer. Modulation of the mechanoenhancer may result in apoptosis, mechanotransduction, proliferation, migration, or growth, or a combination thereof. The compositions and methods may be used to treat disease such as cancer or fibrosis.
20.
PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY
Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
Disclosed herein is a novel Cas9 protein. Further described herein are fusion proteins, compositions, and methods comprising the same. The novel Cas9 protein may be used, for example, in compositions and methods for modulating expression of a gene, for correcting a mutant gene, and for treating a disease.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/90 - Stable introduction of foreign DNA into chromosome
22.
NON-INVASIVE ORTHOSIS FOR IMMOBILIZING THE CERVICAL SPINE
An orthosis is provided for immobilizing a cervical spine including: a forehead band; a back plate having a vertebral void, and a torso harness. The back plate is coupled to the forehead band. The torso harness includes a back plate stabilizer that stabilizes a position of the back plate relative to the cervical spine.
Systems and methods for performing laser lithotripsy include introducing a lithotripsy medium containing nanoparticles into a body cavity comprising target obstructions and applying laser energy through the lithotripsy medium to disrupt the target obstructions. The nanoparticles may have diameters configured to enhance absorption efficiency of the laser energy. The nanoparticles may include organic polymers such as PEDOT: PSS or inorganic compounds such as indium tin oxide. Systems may include a laser source, a fluid delivery component configured to deliver the nanoparticle-containing lithotripsy medium, and an optical fiber for delivering laser energy. Methods of manufacturing lithotripsy media include selecting target wavelengths, synthesizing nanoparticles with corresponding absorption characteristics, and dispersing the nanoparticles at selected concentrations.
A61B 18/24 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibreHand-pieces therefor with a catheter
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention relates to droplet-based surface modification and washing. According to one embodiment, a method of splitting a droplet is provided, the method including providing a droplet microactuator including a droplet including one or more beads and immobilizing at least one of the one or more beads. The method further includes conducting one or more droplet operations to divide the droplet to yield a set of droplets including a droplet including the one or more immobilized beads and a droplet substantially lacking the one or more immobilized beads.
G01N 27/26 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variablesInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by using electrolysis or electrophoresis
B01F 33/302 - Micromixers the materials to be mixed flowing in the form of droplets
B01F 33/3031 - Micromixers using electro-hydrodynamic [EHD] or electro-kinetic [EKI] phenomena to mix or move the fluids
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
25.
METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR EARLY DETECTION OF A NEURODEVELOPMENTAL OR PSYCHIATRIC DISORDER USING SCALABLE COMPUTATIONAL BEHAVIORAL PHENOTYPING AND AUTOMATED MOTOR SKILLS ASSESSMENT
The subject matter described herein includes methods, systems, and computer readable media for early detection of a neurodevelopmental or psychiatric disorder using scalable computational behavioral phenotyping. According to one method for early detection of a neurodevelopmental or psychiatric disorder using scalable computational behavioral phenotyping includes obtaining user related information, wherein the user related information includes metrics derived from a user interacting with one or more applications executing on at least one user device; generating, using the user related information and a machine learning based model, a user assessment report including a prediction value indicating a likelihood that the user has a neurodevelopmental or psychiatric (neurodevelopmental/psychiatric) disorder and a prediction confidence value computed using relative contributions of the metrics to the prediction value generated using the machine learning based model; and providing the user assessment report to a display or a data store.
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
26.
Composition and method for treatment of neuropsychiatric disorders
The present invention relates to a composition and method for combinative therapy, capable of temporarily regulating inherent dysfunctional neural processes and reducing symptoms and/or signs of neuropsychiatric disorders including, but not limited to, psychostimulant use disorder (PUD) and other substance-related additive disorders, post-traumatic stress disorder (PTSD) and other trauma- and stress-related disorders, and levodopa-induced dyskinesia (LID) and other types of dyskinesias. The present specification shows specific examples of a dosage form.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
A61K 31/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
Disclosed herein are methods for the treatment of Pompe Disease comprising administering a recombinant AAV (rAAV) vector comprising a rAVV genome comprising a heterologous nucleic acid encoding an acid alpha-glucosidase (GAA) polypeptide operatively linked to a liver-specific promoter, wherein the subject is withdrawn or not administered enzyme replacement therapy (ERT).
Systems and methods for producing an ultrafast functional photoacoustic microscopy system are disclosed herein. Such systems are configured to enable the imaging of microvasculature and functional dynamics of tissue samples with a broad field of view and high spatial resolution. According to several disclosed embodiments, a combination of a Raman path and a polygon scanner in water immersion and air immersion environments enables rapid imaging of target materials.
G01N 29/22 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object Details
A radio frequency applicator, including a waveguide having a first interior surface comprising a first aperture, a second interior surface opposing the first interior surface, a third interior surface adjacent to the first and second interior surfaces, a fourth interior surface opposing the third interior surface, and a fifth interior surface perpendicular to the first, second, third, and fourth interior surfaces, an aperture antenna, a solid dielectric insert within the waveguide, the solid dielectric insert having a second aperture formed therethrough that is configured for alignment with the first aperture, an RF connector, configured to receive generated RF energy pulses, at least one planar-shaped shim, having a third aperture therethrough configured to align with the first and second apertures, and a radio frequency feed pin connected to the RF connector, disposed within the first, second, and third apertures and affixed to the second interior surface of the waveguide.
A method comprising effecting a change in a shape of a droplet, wherein the droplet is disposed over a substrate in sensing proximity to a sensor and the droplet has a starting surface area exposed to the sensor; and producing an expanded surface area of the droplet in the sensing proximity exposed to the sensor, wherein the expanded surface area exposed to the sensor is greater than the starting surface area exposed to the sensor.
Disclosed herein are compositions for and methods of treating, preventing, and/or mitigating pain, including both acute and chronic pain, post-surgical pain, cancer pain, injury pain, and pain associated with bone fracture. Disclosed herein are compositions for and methods of providing non-opioid analgesia in a subject in need thereof.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Disclosed herein are compositions comprising LNPs capable of selectively targeting cancer cells in organs for the efficient delivery of RNA cargos, specifically aimed at targeting poorly druggable, disease-driving transcription factors in prostate cancer and methods of use thereof.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Cylindrical motion control for an additive manufacturing system includes a cylindrical printing attachment. The cylindrical printing attachment can include a body having a platen-contacting surface for coupling to a platen of the additive manufacturing system, a rack surface, and an axle clamp track; a rack and pinion gear assembly, including a rack and a pinion, wherein the pinion rotatably engages with the rack, wherein the rack is coupled to the rack surface of the body; and an axle clamp structured to rotate along the axle clamp track of the body as the pinion rotates along the rack.
A radio frequency applicator, including a waveguide having a first interior surface comprising a first aperture, a second interior surface opposing the first interior surface, a third interior surface adjacent to the first and second interior surfaces, a fourth interior surface opposing the third interior surface, and a fifth interior surface perpendicular to the first, second, third, and fourth interior surfaces, an aperture antenna, a solid dielectric insert within the waveguide, the solid dielectric insert having a second aperture formed therethrough that is configured for alignment with the first aperture, an RF connector, configured to receive generated RF energy pulses, at least one planar-shaped shim, having a third aperture therethrough configured to align with the first and second apertures, and a radio frequency feed pin connected to the RF connector, disposed within the first, second, and third apertures and affixed to the second interior surface of the waveguide.
The present invention provides protein libraries comprising variants of an antigenic viral protein that each have a different set of mutations at one or more hypervariable sites. Nucleic acid and vector libraries encoding the protein libraries, vaccines comprising the libraries, and methods of inducing an immune response against the antigenic viral protein are also provided.
The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
37.
COMPOSITIONS FOR AND METHOD OF EFFECTING TUMOR CELL DEATH
Disclosed herein are compositions comprising a chimeric antigen receptor targeting phosphatidylserine on the surface of cancer cells and methods of using the compositions to treat a cancer in a subject.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Disclosed herein are chimeric antigen receptors targeting cVIM on the surface of cancer cells. Also disclosed are compositions comprising CARs targeting cVIM and methods of using these compositions to treat cancer and/or slowing disease progression in a subject.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Disclosed herein are compositions comprising a chimeric fusion protein targeting phosphatidylserine on the surface of hematological cancer cells and methods of using the compositions to treat a hematological cancer in a subject.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
A61K 40/15 - Natural-killer [NK] cellsNatural-killer T [NKT] cells
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
Microgel assemblies provide an injectable and tunable microporous scaffold for immune cell modulation. Leukocytes from graft recipients can migrate into and integrate within the microgel assembly to induce immunological tolerance for the graft without the need for chronic immunosuppressive therapy. The microgel assembly can be used to treat for tissue graft and to reduce an alloreactive immune response following a tissue graft.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Disclosed are coronavirus-based immunogens, including immunogens comprising receptor binding domain (RBD), comprised in immunogen displays (e.g., nanoparticles). Provided also are immunogenic compositions and methods of using the compositions to induce immunogenic responses in a subject.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (France)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITÉ PARIS CITÉ (France)
DUKE UNIVERSITY (USA)
UNIVERSITÉ DE MONTPELLIER (France)
ECOLE NATIONALE SUPÉRIEURE DE CHIMIE DE MONTPELLIER (France)
Inventor
Puissant, Alexandre
Wood, Kris
Martin, Anthony
Abstract
γγ-PIK3R5/p101 axis blocks AKT signaling, compromises cell fitness, and sensitizes to established AML therapies. Importantly, the inventors find that existing small molecule inhibitors against PIK3CG are insufficient to achieve a sustained longterm anti-leukemic effect. To address this concern, the inventors developed a proteolysis- targeting chimera (PROTAC) heterobifunctional molecule that specifically degrades PIK3CG and potently suppresses AML progression alone and in combination with venetoclax in human AML cell lines, primary AML patient samples, and syngeneic mouse models.
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/02 - Antineoplastic agents specific for leukemia
43.
EN FACE RETINAL VESSEL SHADOW VIEW OPTICAL COHERENCE TOMOGRAPHY IMAGES
A retinal vessel shadow view optical coherence tomography (RVSV-OCT) image can be created by receiving, at an enhanced OCT processing system, volumetric OCT scan of a patient. The system can segment the volumetric OCT scan to determine layer boundaries and delineate a boundary of interest based on the determined layer boundaries of the segmented volumetric OCT scan. En face vascular information can be extracted to create an RVSV-OCT image by determining a first offset from the boundary of interest and a second offset from the boundary of interest; extracting volumetric data from an area between the first offset and the second offset to create a three-dimensional volume; and identifying a two-dimensional surface from the three-dimensional volume, the two-dimensional surface being the RVSV-OCT image. The RVSV-OCT image can be provided for analysis, for example, to evaluate retinal vascular disease in preterm infants at risk for retinopathy of prematurity.
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
Exemplary layered double hydroxides (LDHs) may comprise a compound of formula Mg4−yAlXy(OH)2, wherein X is Mn+2, Cu+2, Zn+2, or Fe+2, and 0.01≤y≤1. Exemplary layered double hydroxide hydrogels (LDH-gels) may comprise a hydrogel and at least one LDH. Exemplary hydrogels may comprise polyethylene (glycol) diacrylate (PEGDA) or polyacrylamide (PAAm). Exemplary LDH-gels may comprise at least one LDH comprising a compound of formula Mg4−yAlXy(OH)2, wherein X is Mn+2, Cu+2, Zn+2, or Fe+2, and 0.01≤y≤1.
ditert22 catalyst. These resins may also include at least one suitable photoinitiator and, optionally, a light attenuating agent or photoinhibitor. Advantageously, it has been reported that these resins have a complex viscosity that is suitable for 3D printing (from about 0.5 Pa·s to about 20.0 Pa·s) at room temperature without the need for a solvent or other diluent.
Disclosed herein are methods for treating or reducing symptoms of a neurodegenerative disease in a subject. This disclosure relates to a method of restoring the tertiary structure of a mutant C terminus of HSP70-Interacting Protein (CHIP) to the tertiary structure of wild-type CHIP. Also disclosed herein are methods of increasing ubiquitination of a protein by a mutant C terminus of HSP70-Interacting Protein (CHIP) and methods of treating a neurodegenerative disorder comprising administering a therapeutically effective amount of a small molecule or a peptide to a subject.
A61P 25/00 - Drugs for disorders of the nervous system
A61P 37/00 - Drugs for immunological or allergic disorders
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A sono-ink composition is described that includes a acrylate oligomer, an acoustic absorber, and a thermal initiator. A method of using the sono-ink for deep-penetrating volumetric printing is also described. The method includes the steps of a) providing a volume of a sono-ink composition, comprising a acrylate oligomer, an acoustic absorber, and a thermal initiator; b) directing a focused acoustic projection of ultrasound waves into the volume of the sono-ink, wherein the focused acoustic projection of ultrasound waves has an intensity and frequency sufficient to activate the thermal initiator so that local polymerization is achieved at a desired region within the volume of sono-ink; and c) optionally repeating step b wherein the focused acoustic projection of ultrasound waves is directed to selected regions within the sono-ink, until a three-dimensional object is formed.
B29C 35/02 - Heating or curing, e.g. crosslinking or vulcanising
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
B29C 64/165 - Processes of additive manufacturing using a combination of solid and fluid materials, e.g. a powder selectively bound by a liquid binder, catalyst, inhibitor or energy absorber
B33Y 70/10 - Composites of different types of material, e.g. mixtures of ceramics and polymers or mixtures of metals and biomaterials
B33Y 80/00 - Products made by additive manufacturing
C08F 2/56 - Polymerisation initiated by wave energy or particle radiation by ultrasonic vibrations
C08F 265/06 - Polymerisation of acrylate or methacrylate esters on to polymers thereof
C08H 1/00 - Macromolecular products derived from proteins
B29C 64/135 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask the energy source being concentrated, e.g. scanning lasers or focused light sources
48.
IMPROVED TYROSINE HYDROXYLASE PROMOTERS AND NUCLEIC ACID COMPOSITIONS AND USES THEREOF
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
45 - Legal and security services; personal services for individuals.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Grief counseling; Bereavement consulting; Ministerial services; Providing personal support services for patients and families of patients with cancer, namely, emotional counseling and emotional support; Providing personal support services for families of patients with life threatening disorders, namely, companionship, help with medical forms, emotional counseling and emotional support Health care; Blood banks; Dentist services; Emergency medical services; Hospital services; Hospice services; Consulting services in the field of medical care; Nursing care; Optician services; Optometry services; Medical services; Counseling in the field of mental health and wellness; Dispensing of pharmaceuticals; Rental of medical equipment; Home health care services; Providing wellness services, namely, personal assessments, personalized routines, maintenance schedules, and counseling; Charitable services, namely, patient assistance program to provide drugs free of charge to low-income patients without prescription drug coverage
50.
METHODS AND COMPOSITIONS FOR DRUGS TO TREAT OPHTHALMIC DISEASES
The presently disclosed subject matter is directed to compositions and methods for treating CaMKK2-mediated ophthalmic diseases, including but not limited to 1) ocular surface inflammatory diseases (OSIDs), including but not limited to ocular graft versus host disease, ocular cicatricial pemphigoid, vernal keratoconjunctivitis, allergic eye disease, meibomian gland dysfunction, aqueous tear deficiency (common dry eye disease), corneal scarring, and conjunctival scarring and fibrosis; 2) uveitis and other inflammatory diseases of the eye, including but not limited to keratitis, scleritis, iritis, iridocyclitis, intermediate uveitis, pars planitis, posterior uveitis, choroiditis, chorioretinitis, retinitis, or panuveitis of noninfectious, infectious, or idiopathic etiologies; and 3) “back of the eye” retinal diseases, which include dry age-related macular degeneration, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular diseases (e.g. retinal vein occlusion, retinal artery occlusion), and retinal degenerations and dystrophies, in a subject. Particularly, the disclosed compounds exhibit improvements over STO-609, a well characterized specific inhibitor of CaMKK2. The disclosed compounds exhibit enhanced aqueous solubility and formulation, as well as elimination of non-binding isomers during production. The disclosed inhibitor compounds can be used to effectively treat ophthalmic diseases, cancers, appetite disorders, systemic inflammatory diseases, and the like.
Systems and methods for producing a three-dimensional diffractive acoustic tomography system are disclosed herein. Such systems are configured to enable the imaging of microvasculature and functional dynamics of tissue samples with a broad field of view and high spatial resolution. According to several disclosed embodiments, a combination of ultrasonic and photoacoustic imaging combined emitted and received through a slit enables rapid imaging of target materials.
Disclosed are coronavirus-based immunogens, including immunogens comprising spike protein and or domains thereof, comprised in immunogen displays (e.g., nanoparticles). Provided are also immunogenic compositions and methods of using these immunogens to induce immunogenic responses in a subject.
Provided herein are methods and biomarkers useful for detecting and diagnosing osteoarthritis and its severity and predicting the progression of osteoarthritis in subjects. The biomarkers for diagnoses and prognoses may be used to develop treatment plans for subjects.
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
54.
BLOCK COPOLYMER NANOPARTICLES FOR SUSTAINED DRUG DELIVERY
Disclosed herein are POEGMA-based block copolymers that have phase transition and self-assembly properties. The disclosed block copolymers can take advantage of these properties to form particles that can effectively encapsulate and deliver drugs. An example block copolymer includes a first block that includes POEGMA with ethylene glycol side chains of 2 monomers, 3 monomers, or combinations of both; and a second block that includes POEGMA with ethylene glycol side chains of 1 monomer, 2 monomers, or combinations of both. Also disclosed herein are compositions that include the block copolymers, methods of treating a disease or disorder, and methods of delivering a drug.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
A61K 31/726 - Glycosaminoglycans, i.e. mucopolysaccharides
Methods and compositions for promoting donor-specific tolerance and immunocompetence to a recipient of a solid organ transplant, by implanting an allogeneic solid organ in a recipient in need of a solid organ transplant and further comprising surgical implantation of a tissue-engineered allogeneic cultured postnatal thymus tissue product in the recipient of a solid organ from a donor.
A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
A01N 1/162 - Temperature processes, e.g. following predefined temperature changes over time
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
The invention provides competitive inhibitors of farnesyl transferase, compositions comprising the competitive inhibitors of farnesyl transferase, and their use as antifungal agents and as agents for the prevention of the formation or growth of biofilms.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Disclosed are membrane proximal external region (MPER) immunogens from HIV that can stimulate broadly neutralizing antibodies (bnABS), lipid immunogen displays having the MPER immunogens, and methods for stimulating antibodies using the MPER immunogens and lipid immunogen displays.
Disclosed are recombinant proteins encoding HIV-1 fusion peptides and configured for incorporation into an immunogen display (e.g., self-assembling protein nanoparticle). Disclosed are the immunogen displays and methods of using the immunogen displays to stimulate an immune response in a subject.
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.
The technology is directed to HIV envelopes which comprise sequence modifications wherein these modifications prevent CD4-induced transitions of the HIV Env. Provided also are compositions comprising envelopes of the technology, and methods of use.
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/04 - Antineoplastic agents specific for metastasis
Triangle Environmental Health Initiative, LLC (USA)
Duke University (USA)
Inventor
Trotochaud, Lena
Miller, Graham H.
Hawkins, Brian T.
Forbis-Stokes, Aaron
Rogers, Tate
Dutoit, Marielle
Abstract
The present disclosure describes systems and methods for wastewater treatment. In some embodiments, a system may include one or more of a pair of electrodes, a first membrane selectively permeable to a first wastewater nutrient, a second membrane selectively permeable to a second wastewater nutrient, and at least one spacing frame comprising a structural element, a gasket, and a flow channel. In some embodiments, the system may further include a septic tank.
C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
Disclosed herein are binding molecules and/or antibodies targeting a universal influenza antigen and methods of using the same to treat a subject having an influenza infection and to minimize the progression of an influenza infection in a subject.
A method for treating cancer in an individual comprises administering to the individual a therapeutically effective amount of a PCSK9 inhibitor. The method may further comprise administering to the individual at least one immune checkpoint inhibitor.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides a gene delivery system in which transgenic mitochondria are administered to an animal to permit expression of the transgene and secretion of a transgene- encoded protein to an animal.
A DNA synthesis technology that relies on sequence-directed, multiplexed ligations to enable template-independent, exponential synthesis of gene- or genome-length DNA. This approach relies on well characterized and optimized enzymes and thus does not require further protein engineering. This approach is amenable to cost-effective automation and thus will enable cost-effective DNA “printers”.
Disclosed herein are compositions comprising nanoparticles designed for CRISPR/Cas13 RNA targeting systems, specifically aimed at targeting poorly druggable, disease-driving genes in prostate cancer and COVID-19, and methods of use thereof.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Disclosed herein are compositions and methods for modulating T cells. For example, the compositions and methods may be used to increase memory T cells. The compositions and methods may increase the expression or protein level of a transcription factor selected from TGIF2LX, TGIF1, TGIF2, FOS, HNF4A, KLF8, NFKBIZ, CARF, EBF3, HMX3, LHX4, LMX1A, PLAG1, PLAGL1, POU2F3, SOX14, TFAP2D, and WT1, or a combination thereof. The compositions and method may be used in combination with Adoptive T Cell Therapy (ACT) to enhance the ACT.
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
Cellulose-reinforced hydrogels may include a cellulose nanofiber network and an interstitial hydrogel portion within interstitial regions of the cellulose nanofiber network, the interstitial hydrogel portion comprising polyvinyl alcohol (PVA), wherein the hydrogel component has a crystallinity of 20% or greater.
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
An on-spot abnormal tissue detection system includes a light source, a housing, a light fiber, a collimating lens, one or more beam combining mirrors, one or more focusing optic lenses, one or more achromatic doublet lenses, a spectrometer, a fiber optic cable, and a computing system. The computing system can receive wavelength intensity pairs for spot locations of the target area from the spectrometer, determine a standard deviation and variance measurement of the wavelength intensity pairs for the spot locations, determine whether tissue for the spot locations of the target area is a tissue type of a tumor or normal tissue based on the standard deviation and variance measurement of the wavelength intensity pairs, and send the determination of whether the tissue for the spot locations of the target area is a tissue type of a tumor or normal tissue to a display.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
The application is drawn to radiolabeled biomolecules and methods for radiolabeling biomolecules with radioactive halogen atoms that minimizes loss of the radioactive halogen due to dehalogenation in vivo, preserves the biological activity of the biomolecule, maximizes retention of radioactivity in cancer cells, and minimizes the retention of radioactivity in normal tissues after in vivo administration. Some such radiolabeled biomolecules comprise a radioactive metal atom in place of, or in addition to the radioactive halogen. The biomolecules have an affinity for particular types of cells and may specifically bind a certain cell, such as cancer cells. Relevant biomolecules include antibodies, monoclonal antibodies, antibody fragments, peptides, other proteins, nanoparticles and aptamers.
09 - Scientific and electric apparatus and instruments
Goods & Services
Downloadable software for providing training and guidance to caregivers to support child development; Downloadable computer application software for mobile phones and handheld computers, namely, software for providing training and guidance to caregivers to support child development
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 5/00 - Drugs for disorders of the endocrine system
A61P 35/04 - Antineoplastic agents specific for metastasis
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
78.
TEMPLATE DEVICES FOR PLACEMENT OF IMPLANT AND METHODS OF USE
The present disclosure provides devices, systems, and methods relating to performing a medical procedure. In particular, the present disclosure is directed to devices, systems, and methods for accurately positioning and securing a body implant in a subject. A template corresponds to the implant, and the template is configured to mark a desired location in a patient prior to positioning the implant at the desired location.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
The disclosure provides methods of treating cancer, such as an estrogen receptor negative (ER–) solid cancer or estrogen receptor-low (ERlow) solid cancer in a patient. The method may include administering to the patient an effective amount of lasofoxifene, or a pharmaceutically acceptable salt or functional derivative thereof.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Disclosed herein are functionalized branched poly-lysine compounds and uses thereof, as well as delivery systems in which polymeric nanocarriers are functionalized with branched poly-lysine compounds. Also provided herein are uses of the functionalized branched poly-lysine compounds and the delivery systems for treating joint diseases such as osteoarthritis, and in delivering pharmaceutically active compounds to cartilage and subchondral bone.
C08G 69/48 - Polymers modified by chemical after-treatment
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
The present disclosure describes, in part, biomarkers for the identification of aggressive prostate cancer by determining a castration-resistant prostate cancer (CRPC) evolutionary signature of prostate cells, and methods of use thereof.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Disclosed herein are compositions and methods for modulating T cells. For example, the compositions and methods may be used to increase memory T cells. The compositions and methods may increase the expression or protein level of a transcription factor selected from THAP6, DMRT3, MEF2B, PAX2, ATOH7, KLF2, KLF1, TWIST1, NKX6, and FEV, or a combination thereof. The compositions and method may be used in combination with Adoptive T Cell Therapy (ACT) to enhance the ACT.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The Governors of the University of Alberta (Canada)
Inventor
Kaddurah-Daouk, Rima
Wishart, David
Rayat, Dorsa Yahya
Abstract
The present disclosure describes, in part, devices, systems, and methods for connecting metabolomic measurements to big data being generated by sensors captured in databases to enable monitoring of metabolic health at molecular level to map disruptions in biochemical processes in each individual that can inform about basis of disease and ways to correct for such defects tailored for each individual.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 20/90 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to alternative medicines, e.g. homeopathy or oriental medicines
Methods and system for music generation. One method comprises defining a phrase structure and a metrical layout, and generating a melody based on the phrase structure and the metrical layout using a probabilistic model of contour-sequences in a machine learning model. The probabilistic model includes a plurality of production rules determined by the machine learning model trained on a dataset of hierarchical analyses, and the contour-sequences defining directional patterns between musical notes extracted from the dataset of hierarchical analyses.
The Chancellor, Masters and Scholars of the University of Oxford (United Kingdom)
Inventor
Haynes, Barton F.
Saunders, Kevin O.
Li, Dapeng
Azoitei, Mihai
Walters, Lucy C.
Gillespie, Geraldine
Brackenridge, Simon
Mcmichael, Andrew James
Abstract
Recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E-peptide complex, including HLA-E-VL9 complexes, and regulate the cytotoxicity effector cell function of NK and/or CD8+ T-cells positive for cell-surface expression of NKG2A (“NKG2A+”). Herein, monoclonal antibodies were recombinantly derived from isolated functional HLA-E-VL9-specific mAbs from HLA-E-VL9 peptide-immunized HLA-B transgenic mice and from the naive human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The invention provides methods for using HLA-E-VL9 m Abs to modulate NK and/or CD8+ T-cell function as part of immunotherapeutic strategies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Disclosed herein are lipid nanoparticles including a POEGMA-lipid conjugate that can effectively encapsulate and deliver therapeutics without the immune consequences suffered by PEG-based counterparts. An example lipid nanoparticle includes an ionizable lipid, a phospholipid, a sterol, a POEGMA-lipid conjugate, and a therapeutic. Also disclosed herein are pharmaceutical compositions that include the POEGMA-based lipid nanoparticles, methods of treating a disease or disorder, and methods of delivering a therapeutic to a cell.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
88.
COMPOSITIONS AND METHODS FOR IDENTIFYING LIGANDS OF ODORANT RECEPTORS
The present invention relates to compositions and methods for identifying odorant-odorant receptor interactions. In particular, the present invention relates to methods for identifying odorant receptor-odorant interactions based on odorant receptor amino acid sequence and other properties of odorant receptors and odorants. The methods provide, in part, for the broad surveying of OR responses, using an in vivo strategy, against a diverse panel of 10 odorants, followed by using the resulting interaction profiles to uncover relationships between OR responses, odorants, odor molecular properties, and OR sequences.
Genome sequencing identified a new gene associated with a cardiac arrhythmic disease, TAXI -binding protein 3. From cell line models and a conditional knock-out mouse models of the gene deletion, it was found that a specific molecule, transient receptor potential vanilloid 4 (TRPV4), is up-regulated and is associated with calcium mediated arrhythmic depolarizations.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
91.
METHODS, COMPOSITIONS, AND KITS FOR TREATING AND/OR PREVENTING A SIDE EFFECT ASSOCIATED WITH RADIATION AND/OR CHEMOTHERAPY EXPOSURE
Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an active agent at a low dose. In some embodiments, methods, compositions, and kits for treating and/or preventing tissue damage in a subject are provided, including methods, compositions and kits that include an active agent at a low dose.
The present disclosure provides methods of treating or preventing inflammatory bowel disease or sepsis in a subject by inhibiting SUMOylation in the subject.
The present invention provides affinity matured recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E- peptide complex, including HLA-E-VL9 complexes, and regulate the cytotoxicity effector cell function of NK. Herein, monoclonal antibodies were recombinantly derived from isolated functional HLA-E-VL9-specific mAbs from the naïve human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The monoclonal antibodies were subject to one or more rounds of affinity maturation. The invention provides methods for using affinity matured HLA-E-VL9 mAbs to modulate NK cell function as part of immunotherapeutic strategies.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
94.
COMPOSITIONS COMPRISING XBP1 FRAGMENTS AND METHODS OF USE IN GENE THERAPY
Disclosed herein are compositions comprising endoplasmic reticulum (ER) stress sensor variants. Disclosed herein are methods of using the disclosed compositions to maintain and/or establish ER homeostasis following transgene expression.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
95.
ALLOSTERIC MODULATORS OF THE BETA1-ADRENERGIC RECEPTOR AND METHODS OF USING SAME
Described herein are compositions and methods for treating, ameliorating, or inhibiting the progress of blood cancer in a cell or a subject. In some embodiments, the compositions and methods comprise one or more retinoid X receptor (RXR) modulators and one or more immunomodulatory agents. In some embodiments, the blood cancer is multiple myeloma (MM). In some embodiments, the subject has diabetes, dyslipidemia, or a combination thereof.
The present invention provides improved, methods to treat glioblastoma, including newly diagnosed glioblastoma (ndGBM) and recurrent glioblastoma (rGBM), in a human comprising administration to the patient of a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in the poliovirus 5' untranslated region between the poliovirus cloverleaf and the poliovirus open reading frame (a "chimeric poliovirus") by cervical perilymphatic subcutaneous injection, convection enhanced delivery (CED), direct intracavitary infusion via an Ommaya reservoir inserted into the surgical cavity, injection into the glioblastoma lesion cavity wall, or a combination thereof As provided herein, the chimeric poliovims is administered in a specifically-timed treatment regime comprising a treatment phases as a first-line treatment preceding the current standard of care glioblastoma therapy of maximum surgical resection, radiation, and temozolomide.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
99.
ELIMINATION CAPABILITY FOR ACTIVE MACHINE LEARNING
A method of datapoint elimination for an active learning algorithm includes monitoring datapoints in a labeled training dataset as new labeled datapoints are added to the labeled training dataset; determining whether datapoints in the labeled training dataset satisfy a criterion for elimination operations of an elimination protocol; and applying the elimination operations of the elimination protocol to remove one or more datapoints from the labeled training dataset.
A method for dynamically managing an energy system includes determining a production plan by determining a first stochastic system dynamic program (SSDP) based on a state of and a forecasted energy demand in the energy system, determining a second SSDP by relaxing the first SSDP, decomposing the second SSDP into energy unit-specific SSDPs, applying the unit-specific SSDPs with a price model to define a bound on the first SSDP, and determining a forward-looking dynamic economic dispatch plan based on the second SSDP by identifying actions for the energy units corresponding to reachable production levels, applying current unit-specific states and the identified actions to the production plan to generate an updated production plan including unit-specific actions and expected continuation values based on the second SSDP that modify subsequent actions, and dispatching the identified unit-specific actions to the energy system.
